PubMed HealthSearch

PubMed · 64432

["Sugar-agglutinability"].

Abstract

Haemagglutination induced by saccharose is shown to go parallel with a binding of autologous isohaemagglutinin to the surface of erythrocytes. Under suitable conditions, i.e. in the presence of anorganic ions and health, haemagglutinin may be largely separated from the cell surface and the saccharose agglutination may be inhibited. Haemagglutination induced by saccharose will re-appear after agglutinins being re-adsorbed at low incubation temperatures and prolonged incubation time in non-ional as well as ional media. Therefore it is assumed that in the inert non-ional atmosphere the autologous haemagglutinin will produce a phenomenon of agglutination in non-homologous erythrocytes similar to that in homologous cells.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

K J Halbhuber, G Geyer. 1976. ["Sugar-agglutinability"].. https://pubmed.ncbi.nlm.nih.gov/64432/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Routine transfusion of Rh(D)-positive RBCs to Rh(D)-negative patients designated as do not resuscitate conserves Rh(D)-negative red blood cell inventory.

BACKGROUND: A minority of blood donors are Rh(D)-negative, and Rh(D)-negative red blood cell (RBC) products are often overutilized. As such, Rh(D)-negative RBCs may be difficult to maintain in blood bank inventory. STUDY DESIGN AND METHODS: We changed our blood bank laboratory policy to approve non-alloimmunized Rh(D)-negative patients to receive Rh(D)-positive RBCs for routine transfusion under defined criteria. Those criteria included Rh(D)-negative males (all ages) and females (aged >50 years) who were designated as do not resuscitate (DNR), either with or without intubation, in the electronic medical record. RESULTS: From August 15, 2024 through August 15, 2025, a total of 204 Rh(D)-negative patients met the above criteria and were approved to receive routine Rh(D)-positive RBC transfusions. Within that group, 23 patients received Rh(D)-positive RBCs. The remaining patients either did not require transfusion or were issued Rh(D)-negative RBC units. Since implementing this practice, a total of 68 Rh(D)-negative units were conserved during this time frame. Notably, 28 of the 68 units (41%) were type O, Rh(D)-negative. DISCUSSION: Rh(D)-positive RBCs can be routinely given to non-alloimmunized Rh(D)-negative patients who are not at risk for developing hemolytic disease of the fetus and newborn (HDFN). By creating clear guidelines for the routine administration of Rh(D)-positive RBCs to patients who are not at risk for HDFN, the inventory of Rh(D)-negative RBC units can be directed to those patients who would most benefit from this limited resource.

Erythrocytes

Primaquine-induced superoxide production by beta-thalassemic red blood cells.

Primaquine, a prooxidant antimalarial drug, incubated with human red blood cells (RBC) induced marked superoxide generation in the cells as detected by exogenous cytochrome c reduction. In the presence of primaquine, beta-thalassemic RBC produced significantly more superoxide than normal RBC, thus reflecting the vulnerability of beta-thalassemic cells to oxidative stress.

Erythrocytes